|Bid||1.1050 x 0|
|Ask||1.1200 x 0|
|Day's Range||1.1000 - 1.1400|
|52 Week Range||0.9800 - 2.9700|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||36.13|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ACADIA Pharmaceuticals Inc. (ACAD), Neuren Pharmaceuticals Limited (NEU.AX), and Rettsyndrome.org (RSO) announced today that the positive results from a Phase 2 study conducted by Neuren, which evaluated the safety and efficacy of trofinetide in females with Rett syndrome (RTT), have been published in Neurology®, the medical journal of the American Academy of Neurology.
ACADIA Pharmaceuticals Inc. (ACAD) and Neuren Pharmaceuticals Limited (NEU.AX) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America.